BluePrint Orphan

Proven excellence in #orphandrug data analytics, forecasting, ​and market access strategy with a special focus in #RareDiseases *retweets/likes ≠ endorsements*

[BluePrint Orphan @BluePrintOrphan]

Have you been wondering how #COVID19 will affect #orphandrug development? Check out our latest blog post about the pandemic’s impact on the #raredisease sector https://t.co/4jFzJRMhi4

[BluePrint Orphan @BluePrintOrphan]

Highlighting our Patient Subtyping capabilities this month. Want to know more? Contact our team today! #raredisease #orphandrug

[BluePrint Orphan @BluePrintOrphan]

Curious about #raredisease treatment development progress in 2020? Check out some of this year's drug approvals! https://t.co/8zfTWJZW0Q

[BluePrint Orphan @BluePrintOrphan]

Great to see everyone on screen at day 1 of Inborn Errors of Metabolism today! Looking forward to more discussion tomorrow #RareDiseases https://t.co/S40W04UFnU

[BluePrint Orphan @BluePrintOrphan]

Interesting read on how machine learning can be used to help fight #rarediseases https://t.co/cbqAurMgU6

[National Organization for Rare Disorders (NORD) @RareDiseases]

The #NORDSummit will bring #raredisease leaders & stakeholders together to provide new approaches & fresh perspectives on #publicpolicy, clinical trials, access to #diagnostic testing & pharmaceutical innovation. Register or apply for a scholarship: https://t.co/xeG7IVFtKh

[BluePrint Orphan @BluePrintOrphan]

Interesting article highlighting the inherent challenges of #orphandrug research and development - our team is here to help! https://t.co/oP81IuBrgM

[Allucent @Allucent_CRO]

Join our experts for a free webinar: The Value of Orphan Drug Designation in your Drug Development Program
https://t.co/VGNASyau3G
#OrphanDrug #RareDisease #ClinicalDevelopment #Regulatory #FreeWebinar #ClinialTrials #ClinicalStudies #Innovation Cato Research

[National Organization for Rare Disorders (NORD) @RareDiseases]

With the #DISORDER: The #RareDisease Film Festival postponed by the pandemic, the Rare Outreach Coalition decided to start its own streaming channel and bring their content right into your home! Read more: https://t.co/t3WtrUnD5c

[BluePrint Orphan @BluePrintOrphan]

Thanks to these four families and @nytimes for profiling what life with #raredisease is really like - #orphandrugs and treatments are so important https://t.co/0GsQn0WHl9

[BluePrint Orphan @BluePrintOrphan]

Congrats to #IsaPharmaceuticals for receiving @US_FDA #OrphanDrug Designation for ISA101b in HPV16-positive cervical cancer https://t.co/M6Ra15MajC

[RDLA @RareAdvocates]

LAST CALL to register for #RareAcrossAmerica

Check out this article from @healourskin where Shannon von Felden, #RDLA program director, shares everything you need to know about this unique event.
https://t.co/GAbYRHGRaU…/docs/ippf-100-spring-20-issuu/26

[BluePrint Orphan @BluePrintOrphan]

Interesting article on the discovery of novel genetic causes of #rarediseases https://t.co/bBH6Wmc2l4

[National Organization for Rare Disorders (NORD) @RareDiseases]

Join #NORD, @CPathInstitute, @US_FDA and @TakedaPharma tomorrow, June 24 at 2:00 PM ET for “Shortening the Timeline for Developing New Treatments – How the Rare Disease Cures Accelerator–Data and Analytics Platform Can Help.” Register: https://t.co/LFndK4OI2J #RDCADAP #webinar

[BluePrint Orphan @BluePrintOrphan]

Excited to see new funding opportunities for #raredisease research 🎉

[National Organization for Rare Disorders (NORD) @RareDiseases]

The National Organization for Rare Disorders (NORD) is pleased to announce new funding opportunities through the Jayne Holtzer #RareDisease #Research Grants Program. Submission of proposals are due by August 25.

Read more: https://t.co/YVOZuH4PZ9

[BluePrint Orphan @BluePrintOrphan]

Congrats to #ProtagonistTherapeutics on receiving #OrphanDrug Designation for hepcidin mimetic PTG-300

[BluePrint Orphan @BluePrintOrphan]

The @US_FDA has announced that #raredisease patients and #orphandrugs remain priorities during #COVID19 https://t.co/hd7eNagYJ4

[BluePrint Orphan @BluePrintOrphan]

Check out this fascinating development in #raredisease diagnostic technology for childhood genetic conditions https://t.co/Nda8EZ2fMj

[BluePrint Orphan @BluePrintOrphan]

Thanks to Dr. @DavidFajgenbaum for sharing your perspective on how #raredisease and #orphandrug research may apply to #COVID19 https://t.co/hsBQWfZVoL

[BluePrint Orphan @BluePrintOrphan]

Today until July 31, the @US_FDA is seeking comments and feedback from patients, health professionals, and others in the #raredisease community to establish a clinical trials network https://t.co/4gOvBZ2ZlS

[BluePrint Orphan @BluePrintOrphan]

Interesting read on how #orphandrug biotech @Pharnext plans to respond to #COVID19 by leveraging AI data https://t.co/0kvr1C3UxX